Asia Oncology Drug Market Outlook to 2019 - Driven by Rising Demand and Intensifying Joint Ventures between Companies
Region:Asia
Product Code:KR323
June 2015
225
About the Report
The report titled “Asia Oncology Drug Market Outlook to 2019 – Driven by Rising Demand and Intensifying Joint Ventures between Companies” provides a comprehensive analysis of the oncology drug market in Asia. The report covers various aspects such as market size of oncology drugs, segmentation on the basis of therapeutic class, types of cancer, and volume of exports and imports for oncology drugs. The report is useful for pharmaceuticals companies, retail chains, consultants, healthcare professionals and new players venturing in the market. The market is dominated by few global players including Roche, Novartis, Pfizer and others.
Asia Pacific
The Oncology drug market in the Asia, which is hugely driven by rising demand and investment level of government, registered revenues of USD ~ million in 2013. With the advent of new oncology drug manufacturers in the industry, the revenues increased by 7.6% compared to 2013 where the total revenues was USD ~ million. Each segment in the anti-cancer drug market is subject to a gamut of different factors such as prevalence rate of specific type of cancer, price cuts and number of players in the market plays an important role in determining their respective revenues. The oncology drug market of Asia has grown at a CAGR of 4.3% from USD ~ million in’2009 to INR ~ million in 2014. In more developed markets of the Asia-Pacific region, including countries such as Japan and China, the offerings from the market players are expected to be diverse, focused mainly on customized demands. Additionally, the market is predicted to witness expansion in terms of the newer forms of drugs because of rising cancer incidence and growing awareness. The Asia-Pacific oncology drug market is expected to grow at a CAGR of 9.0% from 2015-2019 on account of increasing affluence of consumers towards healthy lifestyles and treatment of cancer in the recent years.
The Asia oncology drug market is dominated by global pharmaceuticals companies that specialize in marketing patented drugs. The market revenues of Roche from sale of anti-cancer drugs have increased noticeably from USD ~ million in 2012 to USD ~ million in 2014, making it the largest player in oncology drug space. Pfizer was the second largest player in 2014. An inclination in the death rates of cancer patients due lack of proper treatment provides a huge opportunity to pharmaceutical companies to deliver effective drugs in the market and thus contributing to higher revenue of anti-cancer drug market.
India
The Oncology drug market in India, which is driven by the development of new alternative therapies, evolving move from chemotherapy to specific cancer targeted therapy, hormone therapy has registered revenues of INR ~ million in 2013. With an entry of new oncology drug manufacturers in the industry, the revenues increased by 65.5% compared to 2013 where the total revenues was INR ~ million. A major factor that has contributed to such a stupendous growth of this market is advances in technologies. Owing to the advancement in technology, the cancer is diagnosed much frequently and thus better treatment can be provided to the patients. The oncology drug market of India has grown at a CAGR of 22.0% from over INR 12 billion in 2009 to INR ~ million in 2014. The main competitors’ in India oncology space includes Cipla Ltd, Sun Pharma Ltd, Dr Reddy Laboratories amongst others. The India oncology drug market is expected to grow at a CAGR of 17.6% from 2015-2019 due to greater influx of patients in cancer care centers due to rising awareness among the people about the right place for best treatment will continue to escalate the growth of oncology treatment in India.
China
Additionally, China has witnessed continuous and substantial rise in the incidence as well as death caused by cancer. This rapid rise has be attributed to factors such as changing lifestyles and dietary patterns, increasing consumption of tobacco, heavy smoking and several other proximate causes. The revenue of oncology market in China increased by 15.0% compared to 2013. The market has grown at a CAGR of 17.3% from USD ~ million in 2009 to USD ~ million in 2014. The market for oncology drugs in China is dominated by local players such as Jiang Su Heng Rui Medicine Co. Ltd, Qilu Pharmaceuticals Co. Ltd and others. The China oncology drug has been anticipated to incline to about USD 30 billion in 2019 from USD ~ billion in 2014. In addition, the share of generic drugs in China Oncology market is expected to rise by a small percentage to around 72% in the year 2019.
The market for oncology drugs in Asia is changing at a rapid rate. Furthermore, new upcoming drugs, investment by government on Healthcare as well as competitive pressures have been significantly changing the market. Revenues from the anti-cancer drug market in the Asia are expected to expand to USD ~ million in 2019 growing with a CAGR of ~% from 2014-2019.
Key Topics Covered in the Report:
- The market size of the oncology drug market in Asia
- The market size of the generic and patented drugs in Asia oncology drug market.
- The market size of the local and global players market Asia oncology drug market.
- The market size of the India oncology and China oncology drug market.
- Market segmentation of the oncology market on the basis of type of cancer, by generic and patented drugs.
- SWOT and Porter Five force Analysis of India and China Oncology Drug market.
- Trends and Development in the Asia oncology drug market.
- Government Regulations in the India and China oncology drug market.
- Competitive landscape detailed company profiles and market share of the major manufacturers of oncology drugs in Asia as well as India, China and others
- Macro Economic factors affecting India and China Oncology drug market.
- Future outlook and projections of Asia Oncology drug market on the basis of – geography.
Products
Generic Cancer Drugs, Patented Cancer Drugs, Chemotherapy, Targeted Therapy, Hormone Therapy, Immuno Therapy, Avsatin, Herceptin, Xalkori, Sutent, Gle
Companies
The Asia oncology drug market revenues have grown at a CAGR of 4.3% from 2009-2014. Boom in ageing population in China and Japan, rising intake of health insurance and an increase in the out of pocket healthcare expenditure will result in increased revenu
Table of Contents
1. Global Oncology Drug Market Introduction and Size, 2009-2014
2. Asia-Pacific Oncology Drug Market
2.1. Asia-Pacific Oncology Drug Market Introduction and Size, 2009-2014
2.2. Asia-Pacific Oncology Drug Market Segmentation, 2014
2.2.1. By Share of Therapeutic Modalities, 2014
2.2.2. By Generic and Patented Drugs, 2014
2.3. Asia-Pacific Oncology Drug Market Growth Drivers and Restraints
2.3.1. Growth Drivers
Rising Incidence And Prevalence Of Various Cancer Types
Growing Importance Of Biological And Targeted Drug Therapies
Expiration of Key Patents
Health-Insurance
2.3.2. Growth Restraints
Expensive Treatment
Competition from Biosimilars
Competition
2.4. Asia-Pacific Oncology Drug Market SWOT Analysis
2.5. Asia-Pacific Oncology Drug Market Trends and Developments
Shift Towards Personalized Medication
Antibody Drug Conjugates (ADC)
Increasing Usage of Combination Therapy
2.6. Asia-Pacific Oncology Drug Market Competitive Landscape
2.6.1. Market Share of Major Pharmaceutical Companies by Revenue, 2014
2.6.2. Drugs in Pipeline in the next 3 years and 5 years
3. India Oncology Drug Market
3.1. India Oncology Market Introduction
3.2. India Oncology Drug Market-Value Chain Analysis
Raw Material Manufacturer
Pharmaceutical Company
Drug Distribution
Medical Service Provider
Health Buyer
3.3. India Oncology Drug Market Size by Revenues, 2009-2014
3.4. India Oncology Drug Market Segmentation
3.4.1. By Share of Therapeutic Modalities, FY’2014
Chemotherapy
Targeted Therapy
Immunotherapy (Biologics Therapy)
Hormone Therapy
3.5. India Cancer Cases Market Segmentation
3.5.1. By Incidence and Mortality, 2009-2014
3.5.2. By Type of Cancer, 2013-2014
3.6. India Oncology Drug Market Growth Drivers and Restraints
3.6.1. Growth Drivers
Rise in Cancer Incidence rates
Health Care Expenditure
Technological Advancement
Rising Penetration of Health Insurance
Influence Through Hospital Channel
Rising Affordability
3.6.2. Growth Restraints
Rising Input Costs of Drugs
High Treatment Cost
High Level of Competition
Rising Demand for Generic Drugs
Lack of Eminent Oncology Specialists
3.7. India Oncology Drug Market SWOT Analysis
3.8. Porter Five Forces Analysis of India Oncology Drug Market
3.9. Trends and Developments in India Oncology Drug Market
Introduction of Improved Drugs and Therapies
Increased Consolidation
Rising Markets for Bio-Similar
Rising Combination Therapies
3.10. Government Regulations And Initiatives in India Oncology Drug Market
3.10.1. Regulatory Bodies
3.10.2. Licensing and Registration of Pharmaceuticals
3.10.3. Drugs and Cosmetics Act, 1940
3.11. India Oncology Drug Market External Scenario
3.11.1. Paclitaxel and Docetaxel
Imports Demand and Value, FY’2009-FY’2014
Export Sales and Revenue, FY’2009-FY’2014
3.11.2. Etoposide
Export Sales and Revenue, FY’2009-FY’2014
3.11.3. Other Anti-Cancer Drugs
Import Demand and Value, FY’2009-FY’2014
Export Sale and Revenue, FY’2009-FY’2014
3.12. Competitive Landscape of Major Players in India Oncology Drug Market
3.13. Company Profiles of Major Players in Oncology Drug Market
3.13.1. Cipla Ltd.
3.13.1.1. Business Overview
3.13.1.2. Business Strategies
3.13.1.3. Financial and Operational Performance, FY’2009-FY’2014
3.13.1.4. Anti-Cancer Product Portfolio
3.13.2. Sun Pharma-Ranbaxy Laboratories Ltd.
3.13.2.1. Business Overview
3.13.2.2. Business Strategies
3.13.2.3. Financial and Operational Performance, 2009-2014
3.13.2.4. Anti-Cancer Product Portfolio
3.13.3. Dr. Reddy Laboratories Limited
3.13.3.1. Business Overview
3.13.3.2. Business Strategies
3.13.3.3. Financial and Operational Performance, FY’2009-FY’2014
3.13.3.4. Anti-Cancer Product Portfolio
3.13.4. NATCO Pharma Ltd.
3.13.4.1. Business Overview
3.13.4.2. Business Strategies
3.13.4.3. Financial and Operating Performance, FY’2009-FY’2014
Anti- Cancer Product Portfolio
3.13.5. Biocon Limited
3.13.5.1. Business Overview
3.13.5.2. Business Strategies
3.13.5.3. Financial and Operating Performance, FY’2009-FY’2014
3.13.5.4. Anti-Cancer Product Portfolio
3.14. India Oncology Drug Market Future Outlook & Projections, FY’ 2015-FY’2019
3.14.1. Cause and Effect Relationship between Independent and Dependent Factors
3.15. India Oncology Drug Market Future projections, FY’2015-FY’2019
3.16. India Oncology Hospital Market
Evolvement of Oncology Hospitals in the Country
List of Major Oncology Specialty Hospitals in India- State Presence and Number of Beds
3.16.1. India Major Oncology Hospitals Market Size, FY’2010-FY’2014
3.16.2. India Major Oncology Hospitals Market Segmentation, FY’2014
By States, FY’2014
By Type of Cancers, FY’2014
3.16.3. Cost of Key Oncology Procedures in India
Average Cost Procedure for Lung Cancer in India
Average Cost Procedure for Breast Cancer in India
3.16.4. Revenue of Major Oncology Hospitals in India, FY’2014
3.16.5. Future Opportunities to Set up Cancer Specialty Centres in Different States Across India
3.17. Macro Economic Factors Affecting India Oncology Drug Market
3.17.1. Population in India, 2009-2019
3.17.2. Personal Disposable Income in India, FY’2009-FY’2019
3.17.3. Total Spending on Healthcare, FY’2009- FY’2019
3.17.4. Number of Hospitals in India, FY’2009-FY’2019
4. China Oncology Drug Market
4.1. China Oncology Drug Market Introduction
4.2. China Oncology Market-Value Chain Analysis
Research and Development
Active Pharmaceutical Ingredients (APIs) Manufacturing
Formulation Manufacturing
Marketing and Distribution
4.3. China Oncology Drug Market Size, 2009-2014
4.4. China Oncology Drug Market Segmentation
4.4.1. By Generic and Patented Drugs, 2014
4.4.2. By Local Players and Multinational Companies, 2014
4.5. China Cancer Cases Market Segmentation
4.5.1. By Incidence and Mortality, 2010-2012
4.5.2. By New Cases Registered, 2009-2011
4.6. Growth Drivers and Restraints for China Oncology Drug Market
4.6.1. Growth Drivers
Rising Spending on HealthCare
Rise in Cancer Incidence Rates
Increasing Expenditure And Knowhow On Advanced Technologies And Equipments
4.6.2. Growth Restraints
Lack of Awareness Among People
Issue Of Delivering Healthcare Services In Non-Urban Areas
Rise in Penetration For Generic Drugs
Rising Cost of Drugs
4.7. SWOT Analysis of China Oncology Drug Market
4.8. Trends and Developments in China Oncology Drug Market
Enhanced Consolidation
Extension in Demand for Oncology Drugs
Move Towards Targeted Therapies
Ensuring Value for Money
Biosimilar Monoclonal Antibodies
4.9. Government Regulations in China Oncology Drug Market
Government Drug Pricing Policy
Intellectual Property Issues
Drug registration, Approval and Manufacturing
Advertising
Pricing
Reimbursement Mechanism
4.10. China Oncology Drug Market Competitive Landscape
4.10.1. Product Portfolio
Jiang Su Heng Rui Medicine Limited
Qilu Pharmaceuticals Co. Ltd
Jiangsu Hansoh Pharmaceutical
Luye Pharma Group
4.11. China Oncology Drug Market Future Outlook and Projections, 2015-2019
Cause and Effect Relationship between Independent and Dependent Factors
4.12. Macro Economic Factors Affecting China Oncology Drug Market
4.12.1. Population in China, 2009-2019
4.12.2. Personal Disposable Income, 2009-2019
4.12.3. Total Spending on Healthcare, 2009-2019
4.12.4. Number of Hospitals, 2009-2019
5. Snapshot on Japan Oncology Drug Market
5.1. SWOT Analysis for Japan Oncology Drug Market
6. Company Profiles for Asia Pacific Oncology Drug Manufacturers
6.1. Roche
6.1.1. Business Overview
6.1.2. Business Strategies
6.1.3. Financial and Operational Performance, 2009-2014
6.1.4. Product Profile
6.2. Pfizer
6.2.1. Business Overview
6.2.2. Business Strategies
6.2.3. Financial Performance, 2009-2014
6.2.4. Product Profile
6.3. Novartis
6.3.1. Business Overview
6.3.2. Business Strategies
6.3.3. Financial and Operational Performance, 2009-2014
6.3.4. Product Profile
6.4. AstraZeneca
6.4.1. Business Overview
6.4.2. Business Strategies
6.4.3. Financial Performance, 2009-2014
6.4.4. Product Profile
6.5. Celegne
6.5.1. Business Overview
6.5.2. Business Strategies
Organizational Structure
6.5.3. Financial Performance, 2009-2014
6.5.4. Product Profile
6.6. Eli-Lilly
6.6.1. Business Overview
6.6.2. Business Strategies
6.6.3. Financial Performance, 2009-2014
6.6.4. Product Profile
6.7. GlaxoSmithKline
6.7.1. Business Overview
6.7.2. Business Strategies
6.7.3. Financial Performance, 2009-2014
6.7.4. Product Profile
7. Asia-Pacific Oncology Drug Market Future Outlook and Projections, 2015-2019
7.1. By Geography
8. Appendix
8.1. Market Definition
8.2. Abbreviations
8.3. Research Methodology
Data Collection Methods
Approach
Variables (Independent and Dependent)
Final Conclusion
8.4. Disclaimer
Why Buy From Us?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.